Credit: Insilico Medicine
Thursday, 10.26.2017, Baltimore, MD, Insilico Medicine, a leader in the field of artificial intelligence, is pleased to announce its founder and CEO, Dr. Alex Zhavoronkov, will present at the Singularity University Exponential Medicine Program in San Diego on Wednesday November 8 in Session XVIII – Future of Pharma.
Dr. Zhavoronkov's session will focus on recent advances in the convergence of the next-generation artificial intelligence and blockchain technologies for drug discovery, biomarker development and personal data management.
Exponential Medicine is a reimagination of the medical conference, providing world-class faculty, innovators and organizations from across the biomedical and technology spectrum. The unique and intensive four-day event explores and leverages the convergence of fast moving technologies in the reinvention and future of health and medicine.
Dr. Zhavoronkov said, "The next paradigm shift in human development will result from the massive convergence of the recent advances in deep learning, blockchain, high performance computing and other IT technologies with the advances in biomedical sciences.
Insilico Medicine is at the forefront of this convergence focusing on human longevity and we are delighted to be a part of the Exponential Medicine experience. The event will provide a platform to share our views on the industry, highlight the most promising trends and accelerate innovation by interacting with some of the most promising people on the planet."
Insilico Medicine was the first company to apply deep generative adversarial networks (GANs) to generate new molecular structures with specified parameters and published seminal papers in Oncotarget and Molecular Pharmaceutics.
Another paper, published in Molecular Pharmaceutics in 2016, received the American Chemical Society Editors' Choice Award for demonstrating the proof of concept of the application of deep neural networks for predicting the therapeutic class of a molecule using the transcriptional response data.
The company partnered with GlaxoSmithKline and other pharmaceutical companies to discover disease targets and generate novel molecules for these targets.
Exponential Medicine is the world's most venerated program in the biomedical technologies, and presenting at the event provides a unique opportunity to share with some of the most respected people in the field.
###
For further information, images or interviews, please contact:
Contact: Qingsong Zhu, PhD – [email protected]
Website: http://www.Insilico.com
About Alex Zhavoronkov
Alex Zhavoronkov, PhD is the CEO of Insilico Medicine, a Baltimore-based leader in the next-generation artificial intelligence and blockchain technologies for drug discovery, biomarker development, and aging research. At Insilico he pioneered the applications of generative adversarial networks and reinforcement learning techniques for generating the novel molecular structures with the desired properties. He set up the R&D centers in 6 countries including Korea, Russia, and Taiwan and launched multiple biomarker initiatives including Young.AI. Prior to founding Insilico Medicine, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, the Biogerontology Research Foundation and YLabs.AI and established AgeNet.net competitions and diversity.AI initiative. Since 2012 he co-authored over 80 peer-reviewed research papers and books including "The Ageless Generation: How Biomedical Advances Will Transform the Global Economy". He is also the co-organizer of the Annual Aging Research for Drug Discovery Forum and the Artificial Intelligence and Blockchain for Healthcare Forum at EMBO/Basel Life, one of Europe's largest industry events in drug discovery.
About Insilico Medicine, Inc
Insilico Medicine, Inc. is an artificial intelligence company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D resources in Belgium, Russia, and the UK sourced through hackathons and competitions.
The company utilizes advances in genomics, big-data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company is pursuing internal drug discovery programs in cancer, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging.
Through its Pharma.AI division, Insilico provides advanced machine learning services to biotechnology, pharmaceutical, and skin care companies, foundations and national governments globally. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. http://www.insilico.com
Media Contact
Qingsong Zhu
[email protected]
443-451-7212
@InSilicoMeds
http://www.insilicomedicine.com
